Forte Biosciences, Inc.
FBRX
Jodie situation report
Forte Biosciences, Inc.'s current read is isolated; its market group is not confirming.
No new filing conclusion is available. 0 of 10 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 3 directly disclosed connections are confirming.
- FBRX's market-adjusted activity becomes unusual and at least one connected name confirms.
Invalidation: The isolated read changes if FBRX's group or a disclosed connection begins moving with it.
Who this business touches
The relationships behind FBRX
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
PKGPackaging Corporation of AmericadistributorMar 31, 2026 ▾
“Packaging and Distribution in the United States If Forte’s products are made available to authorized users of the Federal Supply Schedule of the General Services Administration, additional laws and requirements apply.”
AMGNAmgen Inc.competitorMar 31, 2026 ▾
“For example, the Supreme Court of the United States held in Amgen v.”
SNYSanoficompetitorMar 31, 2026 ▾
“Sanofi (2023) that a functionally claimed genus was invalid for failing to comply with the enablement requirement of the Patent Act.”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 2 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
FBRX is currently a Follower in the organic co-movement group Healthcare Biotech & Finance. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.
This group is retained as the last observed read for FBRX; it is not active in the latest market snapshot.